Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 188 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release distributed via Newsfile Corp announcing the company’s view on a recent U.S. executive order and its strategic implications. It does not present financial results, management changes, or formal regulatory filings, nor is it a report itself (e.g., 10-K or interim report). It is a general business update that does not fit any specific category, so it falls under the fallback category for miscellaneous regulatory/general announcements (RNS).
2026-04-21 English
News release - English.pdf
Regulatory Filings
2026-04-20 English
News release - English.pdf
Regulatory Filings
2026-04-20 English
News release - English.pdf
Capital/Financing Update Classification · 88% confidence The document is a full Subscription Receipt Agreement among Nouveau Monde Graphite Inc., underwriters, and a trust company, detailing the issuance, escrow, conversion, and financial terms for subscription receipts. It constitutes a legal financing arrangement for raising capital rather than an annual report, earnings release, or management announcement. Therefore it best fits the Capital/Financing Update category.
2026-04-16 English
News release - English.pdf
Regulatory Filings Classification · 93% confidence The document is a corporate press release (news release) about PharmaTher’s support for proposed FDA peptide reclassification and related strategic initiatives. It does not present financial results (Earnings Release), is not an Annual or Interim Report, not a call transcript, not a board change, dividend, or capital transaction, nor does it announce publication of a report. It is a general corporate/regulatory announcement that does not fit any more specific category. Therefore, it falls into the fallback category for miscellaneous regulatory announcements.
2026-04-16 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing the filing of a U.S. provisional patent application. It does not contain financial results, earnings metrics, AGM materials, or details on share transactions, dividends, or management changes. It is not a formal annual or interim report, nor is it a detailed investor presentation. It fits the residual category of general regulatory or corporate announcements that do not fall under other specific filing types. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.